Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lucy Cook
Oligonucleotide Manufacturing: Take Control Of Your Process
By Lucy Cook, Ph.D. Global Marketing Manager for Nucleic Acid Therapeutics If you are involved in the development of antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutics, you are likely well aware of the significant potential these molecules hold. To effectively tap into this potential, it is crucial to focus on key aspects during the early stages of process development for oligonucleotide therapeutics.
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP - Bone Marrow Transplantation
Abstract Adult T-cell leukemia/lymphoma (ATLL) is a rare HTLV-1-associated malignancy with a dismal prognosis due to intrinsic chemoresistance and immunosuppression. This retrospective EBMT registry analysis evaluated outcomes of allogeneic stem cell transplantation (allo-SCT) in 73 ATLL patients transplanted between 2004 and 2021. With a median follow-up of 3.9 years, 2-year overall survival (OS) and progression-free survival (PFS) were 49% (95% CI 37–60) and 43% (95% CI 31–54), respectively.
06.04.25 -- Improving LNP Formulation For RNA Therapeutic Applications
Webinar: Scaling up your E. coli pDNA process from parameter screening to pilot scale with advanced single-use bioreactors Part 1 in an exciting 3-part webinar series to accelerate your pDNA and mRNA process development. Click here to learn more. On this week's Business of Biotech, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA.
12.05.24 -- Facilities Design/Manufacturing Controls
Transforming the Biopharma Supply Chain and Analytics Capabilities with eData Experience the digital transformation in biomanufacturing! Explore the benefits of eData, the challenges on the journey, and the eMERGE™ Electronic Data Sharing Program. Join the eData Movement. FOCUS ON FACILITIES DESIGN & MAINTENANCE It will be the first country to introduce a tailored framework for innovative medicine manufacturers at or close to where patients receive care.
05.30.24 -- 7 Bioprocess Intensification Strategies
Webinar: Measuring Viral Vector Purity, Stability, and Physical Titer in Minutes — with Just One Tool Industry expert Dr. Laura Pala will highlight the advantages of macro mass photometry to characterize viral vector purity and stability, and help you understand how the KaritroMP can quickly assess the purity of AdV preparations, quantifying empty capsids and other impurities. Click here to learn more.
Imagine The Future: Enhanced Oligonucleotide Synthesis
Article | March 4, 2024 By Lucy Cook, Ph.D. Senior Global Marketing Manager for Nucleic Acid Therapeutics With the right software, even a chemist lacking experience in oligonucleotide synthesis can feel confident their first attempt will be successful. The introduction of UNICORN™ 7 software has revolutionized the way that method creation, evaluation, and process optimizations for scale-up are completed.
Imagine The Future: Enhanced Oligonucleotide Synthesis
Article | March 4, 2024 By Lucy Cook, Ph.D. Senior Global Marketing Manager for Nucleic Acid Therapeutics With the right software, even a chemist lacking experience in oligonucleotide synthesis can feel confident their first attempt will be successful. The introduction of UNICORN™ 7 software has revolutionized the way that method creation, evaluation, and process optimizations for scale-up are completed.
Imagine The Future: Enhanced Oligonucleotide Synthesis
Article | March 4, 2024 By Lucy Cook, Ph.D. Senior Global Marketing Manager for Nucleic Acid Therapeutics With the right software, even a chemist lacking experience in oligonucleotide synthesis can feel confident their first attempt will be successful. The introduction of UNICORN™ 7 software has revolutionized the way that method creation, evaluation, and process optimizations for scale-up are completed.
Nottingham Light Night
Illuminate your imagination as Nottingham Light Night returns to the city centre this February. The castle grounds will be open from 5pm-10pm (last entry 9pm) with free entry for Light Night on Friday 2 and Saturday 3 February 2024. The grounds will be hosting a collection of neon lights by Chila Kumari Burman, whose work has recently been shown in Manchester, Brighton, and London’s Tate Britain.
12.20.23 -- Understanding The Importance Of Real-Time Monitoring For Protein Aggregation
This article breaks down the advantages of real-time monitoring for protein therapeutics, including how it can accelerate timelines, produce better data, and smooth regulatory compliance. On this week's episode of the Business of Biotech, we welcome two extraordinary guests - Dr. Neela Patel, a molecular biologist-turned-Chief Business Officer, and Dr. John Mulligan, an academic-turned-founder of newly-formed Bonum Therapeutics.
Imagine the future: enhanced oligonucleotide synthesis - Cytiva
Imagine a chemist with little experience in oligonucleotide synthesis having confidence that their method will work first time. It can happen with a little help from the right software. UNICORN™ 7.10 software has changed the way method creation, evaluation, and process optimizations for scale-up are accomplished.
Oligonucleotide manufacturing: take control of your process - Cytiva
Oligonucleotide (or oligo) therapeutics are synthetic strands of DNA or RNA that bind specifically to a target gene or protein sequence. Because of their high specificity, oligonucleotides, which include ASOs based on DNA, small interfering RNAs (siRNAs), and other oligonucleotide variants, show promise for treating cancers, genetic diseases, and other conditions. They’re also used in applications such as CRISPR-mediated gene editing.
Developing oligonucleotide therapeutics with confidence
Cell and Gene Therapy Insights 2023; 9(7), 897 10.18609/cgti.2023.114 Lucy Cook Watch the video or read the poster to learn about: A market view of oligonucleotide therapeutics An overview of therapeutics in development, and challenges being addressed by current and future developers Key considerations for those considering starting synthesis and/or future manufacturing of oligonucleotides Information on how to scale up manufacturing Please enter your email to access content Please note...
Oligonucleotide Manufacturing: How To Get A Strong Start
Article | July 26, 2023 By Lucy Cook, Ph.D. Global Marketing Manager for Nucleic Acid Therapeutics If you are involved in the development of antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutics, you are likely well aware of the significant potential these molecules hold. To effectively tap into this potential, it is crucial to focus on key aspects during the early stages of process development for oligonucleotide therapeutics.
Oligonucleotide Manufacturing: How To Get A Strong Start
Article | July 26, 2023 By Lucy Cook, Ph.D. Global Marketing Manager for Nucleic Acid Therapeutics If you are involved in the development of antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutics, you are likely well aware of the significant potential these molecules hold. To effectively tap into this potential, it is crucial to focus on key aspects during the early stages of process development for oligonucleotide therapeutics.
Oligonucleotide Manufacturing: How To Get A Strong Start
Article | July 26, 2023 By Lucy Cook, Ph.D. Global Marketing Manager for Nucleic Acid Therapeutics If you are involved in the development of antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutics, you are likely well aware of the significant potential these molecules hold. To effectively tap into this potential, it is crucial to focus on key aspects during the early stages of process development for oligonucleotide therapeutics.
Oligonucleotide manufacturing: how to get a strong start - Cytiva
If you’re developing an antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutic, you’re already aware of the promise these molecules have. So how can you harness this potential? The first step is knowing where to focus in the early stages of process development for oligonucleotide therapeutics. Choices you make now can have huge impacts later on. This includes speed to market, regulatory acceptance, manufacturing costs, and achieving process sustainability at large scale.
Military eyes bats' 'super-immunity' to combat bioweapons
The U.S. military has a long history of enlisting the help of animals in warfare. The bottlenose dolphin's sophisticated bio sonar enabled the Navy to detect and clear underwater bombs during the Iraq War, and homing pigeons played a vital role as secret messengers during both world wars, with some awarded medals for bravery. But there is one animal the military has had significantly less success in conscripting, and that is the bat.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lucy
Contact Lucy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack